Bolt Biotherapeutics (BOLT) EBITDA Margin (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted EBITDA Margin of 29234.62% for Q1 2026, down 10215.67% sequentially from 283.4% in Q4 2025, and down 2824321.0% YoY from N/an in Q1 2025.
Bolt Biotherapeutics (BOLT) EBITDA Margin (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported EBITDA Margin for 7 years, with the latest figure at 29234.62% in Q1 2026.
- Quarterly EBITDA Margin fell 2824321.0% year-over-year to 29234.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 486.21% (up 138490.0% YoY) and the FY2025 annual result came in at 469.3%, up 48060.0% from the prior year.
- EBITDA Margin fell to 29234.62% in Q1 2026 per BOLT's latest filing, from 283.4% in the prior quarter.
- Over five years, EBITDA Margin peaked at 283.4% in Q4 2025 and troughed at 29234.62% in Q1 2026.
- A 5-year average of 2881.99% and a median of 1033.27% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin jumped 383858 bps in 2022, then sank 2824321 bps in 2026.
- Over 5 years, EBITDA Margin stood at 1491.14% in 2022, then soared by 37 bps to 946.19% in 2023, then slumped by 52 bps to 1441.1% in 2024, then soared by 80 bps to 283.4% in 2025, then sank by 10216 bps to 29234.62% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 29234.62%, 283.4%, and 355.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | -167,480.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -167,480.00% |
| Mar 31, 2026 | -29,234.62% |
| Dec 31, 2025 | -283.40% |
| Sep 30, 2025 | -355.14% |
| Jun 30, 2025 | -510.53% |
| Mar 31, 2025 | -991.41% |
| Sep 30, 2024 | -1,441.10% |
| Jun 30, 2024 | -1,772.31% |
| Mar 31, 2024 | -324.08% |
| Dec 31, 2023 | -946.19% |
| Sep 30, 2023 | -719.26% |
| Jun 30, 2023 | -1,383.95% |
| Mar 31, 2023 | -1,008.49% |
| Dec 31, 2022 | -1,491.14% |
| Sep 30, 2022 | -1,058.05% |
| Jun 30, 2022 | -1,655.35% |
| Mar 31, 2022 | -2,936.78% |
| Dec 31, 2021 | -5,329.72% |
| Sep 30, 2021 | -3,128.46% |
| Jun 30, 2020 | -16,582.09% |